Sentences with phrase «anti-keynesian austerity program»

But to the government's credit, it has hit most of its spending targets in the first few years of the austerity program Flaherty.

As Globe columnist Neil Reynolds recently noted, the IMF has called on the United States and Europe to abandon austerity programs before either had put any in place.

The first group of so - called debt hawks sees another Great Recession coming and wants national governments to focus on austerity programs aimed at deficit reduction because rising sovereign debts are behind our current economic woes.

«Their numbers aren't so bad, but to continue those policies without enacting a relatively strong fiscal austerity program is going to cause problems.»

Even with austerity programs in place, the eurozone's collective budget deficit this year will exceed 4.5 % of GDP.

Supporters point to Ireland, Portugal and Spain as nations that have bounced back to varying degrees after austerity programs; critics point to Greece, which has remained economically troubled.

Toward debtor countries American diplomats work through the World Bank and IMF to demand that debtors raise their interest rates and impose taxes and austerity programs to keep their wages low, sell off their public domain to pay their foreign debts, and deregulate their economy so as to enable foreign investors to privatize local electricity, telephone services and other infrastructure formerly provided at subsidized rates to help these economies grow.

The situation becomes worse as the government borrows from the IMF and is forced to enact an anti-Keynesian austerity program.

This monetarist theory has guided Russian economic reform (and its quick bankruptcy) under Yeltsin and his oligarchy, as well as Chile's privatization (and early bankruptcy) under Gen. Pinochet, and the austerity programs (and subsequent bankruptcies and national resource sell offs) imposed by the IMF on third world debtor countries.

The irony is that while Russia is being told that taking this advice will help make it an American - style economy, Republican congressmen in the United States have been denouncing the IMF and its austerity programs.

The phenomenon is now recognized as an inherent stage of austerity programs.

After more than two years of financial crisis, international bailouts, a huge debt writedown and Europe's harshest austerity program, Greek voters have been given a chance to hit back at the parties that got them into this mess.

The so - called austerity programs of bailout # 1 have not been fully implemented, and none of the austerity from bailout # 2 has been implemented.

For weaker economies in the euro zone that are seeing subdued domestic demand as a result of austerity programs, there were also encouraging signs in the trade figures for August.

The accompanying chart shows the incredible impact of the ongoing austerity programs in Europe.

From New York City's bankruptcy to Puerto Rico's insolvency and Third World debtors subjected to IMF «austerity programs,» national bankruptcies shift control to centralized financial planners in what Naomi Klein has called Crisis Capitalism.

The shares have been weak, like we have seen for many European industrial companies, because investors fear that government austerity programs may precipitate a European recession.

After a contentious period of negotiations, the odds of a so - called «Grexit,» or Greek exit from the euro, were drastically reduced as Greece begrudgingly accepted an austerity program and Germany gave the European Stability Mechanism the green light to negotiate a third bailout.

In Syriza's case, for example, it campaigned on a promise to end the former administration's austerity programs.

Austerity programs similar to those imposed on third - world countries by the International Monetary Fund may soon be required of the United States.

Up until 2012, Chinese drinkers had been devouring Australian wine, but Beijing's anti-corruption drive, along with a broader austerity program, has smashed demand for luxury goods, from wine to Ferraris, and pinched local wine exports to the region.

He only started talking about the austerity program recently so do nt think he had been informed about this clearly before joining

But it has engaged in some austerity programs.

They're making off - the - record jokes about Angela Merkel and the EU's austerity program.

A ComRes poll for today's Independent has shown that 72 % of the public would like to see a change in the government's flagship austerity program.

Greece, Spain, Italy and other countries flirted with disaster as interest rates spiked, forcing the debtor nations to accept austerity programs.

In response to the dawn of the financial crisis, in 2010 the Greek government along with Troika (European Union (EU), the International Monetary Fund (IMF) and the European Central Bank (ECB) introduced a strict austerity program in order to receive its first bailout loan.

While Chinese President Xi Jinping's austerity program and anti-corruption drive have hurt sales of everything from Rolex watches to first growth Bordeaux wines in Hong Kong, the top end of the art market is thriving.

«But as things get worse for Ontario's workers we've seen new levels of cooperation between injured workers, advocates, legal experts, labour unions, doctors and more, all coming together to fight against Ontario's austerity programs

«But as things get worse for Ontario's workers we've seen new levels of cooperation between injured workers, advocates, legal experts, labour unions, doctors and more, all coming together to fight against Ontario's austerity programs and fight for just compensation.»

A few years ago, the EU put Greece under a severe austerity program, but it did nothing but anger the Greek citizenry, who then recently elected a left - wing government that promised them a more splendiferous future.

Akin Gump Strauss Hauer & Feld, where RPL rose 12.9 percent, to $ 965,000, spent much of 2008 in an austerity program, eventually shedding 56 partners, a 16.9 percent reduction.

It's hard to stick to a total austerity program for long.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

But as cities, counties and states compete for economic development, spending on such programs nationwide has climbed into the billions of dollars, even in an era of fiscal austerity.

If you didn't major in economics or you have no clue what austerity means, read on to find out how this fiscal program works.

Growth in most of the eurozone has remained tepid and reliant on continued central bank stimulus, though the European Central Bank's (ECB's) bond - purchasing program has been hampered by a scarcity of eligible bonds, as issuance from member governments is restricted by their austerity - driven policies.

Many analysts have long flagged a similar pitfall for the ECB's purchasing program, namely a scarcity of eligible bonds, as issuance from member governments has been restricted by their austerity - driven policies.

The character of this suffering moves theological attention to the social systems that shape our lives — economic, political, cultural — as well as to public events themselves (the Holocaust, programs and policies of economic austerity, military intervention, terrorism, ethnic nationalist expression, struggles for survival and freedom).

It is largely accepted that these programs lead to systemic macroeconomic instability across the continent and that these policies drove countries of the global south into «debt crisis, austerity, decline and conflict» (Bond) and «acute material scarcity» (Mbembe).

A faction of the Republican Party is pushing austerity budgets, including cuts to social programs that are popular with the middle class, such as Social Security (government - funded retirement pension) and Medicare (government - funded retirement health insurance).

Last week the City Council approved Mayor Bloomberg's $ 63 billion «austerity» budget, cutting funds for schools, libraries and social programs.

Prior to the legislature's proposal for increased taxes, Vanderhoef had presented an austerity budget that called for the immediate sale of Summit Park as well as massive cuts in many other programs.

Some economists want to claim that austerity measures HAVE been tried, and, since we're still in a recession / depression, austerity is therefore a failed «research program» / economic practice.

Obama intended the prospect of the fiscal cliff's dramatic mandatory cuts in social programs to extort progressive Congressional Democrats into agreeing to inflict severe austerity by voting in favor of what Obama hoped would be massive cuts in social programs and the safety net adopted by the Congressional «super committee» created by the same bipartisan austerity deal that created the «fiscal cliff.»

Stuckler and Basu argue that the harsh austerity measures and cutting of social programs adopted in response to the recent financial crisis have exacerbated public health problems and cost thousands of lives.

Weingarten defended «the promise and potential of the Common Core standards,» while warning the program «may actually fail» due to testing backlash, accountability and austerity hawks, and implementation worse than Obamacare's.

Carr also explained that local school districts aggressively engage in competitive grant programs because in a time of austerity, it's imperative they find other revenue streams to support the needs of their traditional public schools.

While Van den Dorpel speaks through the specialized language of computer programming and perhaps abstrusely anthropomorphizes variably folk or «traditional» approaches to fine art, his work addresses more universal concerns related to ethics of economic austerity as well as those of inclusion, alienation, and social hierarchies.

Budget austerity is running rampant through Congress and no program — whether it's vital investments in economic growth or not — is safe.